If you have Medicaid and depression that will not lift, you may have heard, or quietly assumed, that the newer treatments are not meant for you. That assumption is worth testing, because it can keep people from asking a question whose answer might be yes.
Our summer questionnaire, completed by 443 adults in a ten-state slice of the Midwest, produced one especially clear result about who carries which coverage, and it cuts against several common beliefs. Five of them are checked below, using the final, validated figures.
Myth one: "Hardly anyone looking into this care is on Medicaid."
What we found: Medicaid showed up for 37 percent of respondents, a hair behind the 39 percent with commercial insurance and far ahead of every other type. Medicare accounted for 23 percent; TRICARE for 5 percent; no coverage for 9 percent. People could list more than one.
Those two points between Medicaid and commercial coverage are not a meaningful gap. What is meaningful is that the two are essentially level. If you have Medicaid, you are not at the edge of this conversation. You are at the center of it.
Myth two: "Medicaid does not cover FDA-approved newer treatments."
The reality: it depends on your state and your plan, and the only way to know is to ask. Spravato, which is esketamine delivered by nasal spray, won FDA approval for adults whose depression held on through prior antidepressant trials. That approval gives insurers, including Medicaid programs, a clear basis for coverage. Many Medicaid plans that cover it require prior authorization and documentation of past medications.
What is often not covered is ketamine offered outside that approval, such as IV infusions at some clinics or at-home programs. People sometimes hear "ketamine isn't covered" and assume it applies to esketamine too. Those are different things, and the difference matters.
Myth three: "If I mention Medicaid, I will get turned away, so I should lead with something else."
The reality: say it first. Some clinics do not accept Medicaid, and it is far better to find that out on the first call than after an evaluation. Being upfront also helps your doctor refer you somewhere that fits.
Coverage is not a small thing for most people, whatever their plan. On the provider question, where each person could pick two traits, insurance appeared for 85 percent of our respondents, while for 65 percent coverage could decide, or heavily sway, whether they try the treatment. Naming your plan is not an admission. It is the most useful piece of information you can give.
A good opening line on the phone: "I have Medicaid through [plan name]. Do you accept it for esketamine treatment, and if not, do you know who does?"
Myth four: "Medicaid paperwork is so heavy that it is not worth trying."
The reality: paperwork is real, but it is usually manageable with help, and most people are willing to put up with it. Offered an insured path with extra steps or a simpler cash path, just over half of our respondents took insurance, while the others divided about equally between paying and not knowing.
The hoops for esketamine usually look like this: an evaluation, a record of antidepressants you have tried, and a prior authorization request that your prescriber submits. You are not expected to handle it alone; many managed care plans assign care coordinators who help with behavioral health services. Brain Recovery Centers also explains esketamine costs and coverage in plain language for Medicaid members.
Myth five: "If the nearest clinic does not take Medicaid, there is no path."
The reality: there are usually more doors than the first one. A few worth knowing:
- Your plan's member services line can tell you which in-network certified sites exist in your region, even if they are not the closest.
- Community mental health centers frequently accept Medicaid and can provide evaluations and referrals.
- Medicaid plans often pay for rides to medical visits, useful because esketamine means a long observation stay and no driving afterward.
- Esketamine is one option among several once medications have failed. A psychiatrist can talk through others, including therapy approaches and treatments like TMS, which some plans also cover.
Distance is a genuine concern, and you are right to weigh it. A nearby site mattered to 43 percent of our respondents, who ranked it just behind coverage. But a longer drive to a covered site is sometimes more workable than a short drive to one that is not.
Where to start
The most common first step in our survey was also the simplest. A primary doctor was the chosen first stop for 56 percent of respondents, and a psychiatrist for 23 percent. That is a sensible path for Medicaid members, because a primary care provider can document your history for prior authorization and refer you within your plan's network.
People trust that route, too. Their own physician's recommendation was the thing that would move 74 percent of respondents to try it. Ads barely registered at 2 percent.
So if you have been waiting for permission to ask, consider this it. Bring your card, your medication history, and the question: "Is something like esketamine a possibility for me under my plan?"
What this article does not say
It does not say your plan covers esketamine, and it does not say esketamine is right for you. Its approval covers one condition, responses vary, and it does not suit everyone. You and your clinician make that call, and this article is not medical advice.
A crisis needs no plan or paperwork. Use 988, spoken or texted. That Suicide and Crisis Lifeline number charges no one, Medicaid or not, at any hour.
Methodology
Consumer-panel members answered Pollfish survey 395586438 through June 23, 2026; the final count is 443, all aged 18 to 64, across Kansas, Nebraska, Missouri, Ohio, Iowa, Oklahoma, Illinois, Indiana, Minnesota and Wisconsin. Coverage type was multi-select, so totals pass 100. We show validated overall figures. The publisher commissioned this research and bore its cost.